An interventional study of Telemonitoring group and Usual Care Group in Diabete Mellitus and Telemonitoring, sponsored by University of Monastir. Recruiting at 1 site in Tunisia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by University of Monastir · Not applicable, Interventional, and Health services research
Among 20 studies in Diabetes Mellitus with a site in Tunisia — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus · Tunisia.
Among the 20 studies in Diabetes Mellitus with a site in Tunisia, this one is one of 2 that started in 2024, is one of 3 with no phase, and was the 20th registered.
8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.
This study's planned enrollment of 260 is above the median of 80 across 6,023 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →3 of the 20 studies in Diabetes Mellitus with a site in Tunisia are open now, in 1 country. Each count lists the studies.
Of the 651 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 198 (30%) stop at 75 or younger; 87 take children under 18; 183 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →20 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2024.
Median enrollment 155 across the 9 interventional studies, 866 across the 11 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
7 of 20 have an industry lead sponsor. The 10 most frequent:
University of Monastir is the lead sponsor of 114 studies on the registry; 29 are open to participants now.
University of Monastir has 6 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes Mellitus with a site in Tunisia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07774078University of MonastirEffectiveness and Utility of Telemonitoring in Improving the Glycaemic Control of Diabetes Mellitus Tunisian Patients | 2026-12-31 |
Among the 20 studies in Diabetes Mellitus with a site in Tunisia, from their registry updates:
The study aims to evaluate the impact of a telemonitoring system on glycemic control in patients with diabetes in Tunisia. Participants in the intervention group will receive remote diabetes management through a dedicated mobile application and web platform, while the control group will receive standard diabetes care. The primary objective is to determine the effectiveness of telemonitoring in improving glycemic control, as assessed by changes in glycated hemoglobin (HbA1c) and blood glucose levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the telemonitoring group receive a connected blood glucose meter, which automatically transmits all blood glucose readings to a dedicated online telemonitoring platform.
Device: Telemonitoring group
Participants in the usual care group will receive standard diabetes management according to routine clinical practice, at the discretion of their treating physicians. The standard follow-up will include at least three scheduled study visits at Day 15, Month 3, and Month 6. The same clinical and study data will be collected at each visit as in the telemonitoring group.
Other: Usual Care Group
Participants in the telemonitoring group receive a connected blood glucose meter, which automatically transmits all blood glucose readings to a dedicated online telemonitoring platform.
Standard follow-up will including at least three scheduled study visits at Day 15, Month 3, and Month 6.
Change in Blood Glucose Level (mmol/L)
Change in blood glucose level, measured in mmol/L, from baseline to 6 months, comparing the telemonitoring group with the standard diabetes care group.
Time frame: Baseline to 6 months
Change in Glycated Hemoglobin (HbA1c) (%)
Change in glycated hemoglobin (HbA1c), measured as a percentage (%), from baseline to 6 months, comparing the telemonitoring group with the standard diabetes care group.
Time frame: Baseline to 6 months
Change in body weight
Time frame: Baseline to 6 months
Change in body mass index (BMI)
Time frame: Baseline to 6 months
Change in urinary albumin concentration measured in mg/L.
Time frame: Baseline to 6 months
Medication adherence assessed by MARS-5
Time frame: Baseline to 6 months
Medication adherence assessed by Medication Possession Ratio (MPR)
Time frame: Baseline to 6 months
Change in Skin Autofluorescence (AGEs) Measured by AGE Reader
Skin autofluorescence, reflecting tissue accumulation of advanced glycation end-products (AGEs), will be measured using the AGE Reader. The change in skin autofluorescence from baseline to 6 months will be reported.
Time frame: Baseline to 6 months
Change in reactive hyperemia index (RHI)
Time frame: Baseline to 6 months
Number of Participants with Hospitalizations
Time frame: Baseline to 6 months
Number of Participants with Emergency Department Visits
Time frame: Baseline to 6 months
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 1,583 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 28 months is above that.
Counting every sponsor, half of 1,743 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.